StandoutStocks.com: StandoutStocks.com "Stocks that Standout" today are: CEXI, NNVC, REMI, SMAS, VSPC

Aug 25, 2008 (M2 PRESSWIRE via COMTEX) -- VSPC | Quote | Chart | News | PowerRating -- StandoutStocks.com "Stocks that Standout" today are: CDEX, Inc. (OTCBB: CEXI), NanoViricides, Inc. (OTCBB: NNVC), Remedent, Inc. (OTCBB: REMI), Somatic Systems, Inc. (PINKSHEETS: SMAS), VIASPACE Inc. (OTCBB: VSPC)...and Proudly Introducing Proprietary Push Technology (PPT).

The Newest and Revolutionary Technology for Increasing Investor Visability.

REAL Awareness for REAL Companies.

Click below for a full demonstration.

http://newmediaadvisors.info/newmedia.swf

Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at www.Standoutstocks.com

Aug 25, 2008 -- CDEX, Inc. (OTCBB: CEXI), a technology development company, today announced that the company's CEO, Malcolm Philips, is featured in an exclusive interview on WallSt.net's 3-Minute Press Show.

The interview gives viewers an overview of the company, and the significance of the company's latest press release.

To view the clip in its entirety, visit: http://www.tv.wallst.net/r/3-minute-press/Malcolm-Philips-CEXI/218/921

About CDEX:

CDEX is a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technology. The company provides unique solutions to the challenges of identifying substances in difficult to monitor environments. CDEX technology is being adapted to market needs for medication validation, hazardous chemicals detection, and brand protection through analysis of counterfeit substances.

CDEX is currently organized to serve two critical markets -- Medication Safety and Security. The ValiMed System(TM) is providing life-saving validation of high-risk medications as well as identifying narcotics diversion in healthcare facilities and pharmacies around the world.

The ID2 Meth Scanner(TM) is a revolutionary new tool in the global battle against the growing scourge of methamphetamine abuse and its toxic impact on the general public. Corporate headquarters and R&D facilities are located in Tucson, Arizona with international offices in Paris, France.

Aug 25, 2008 -- NanoViricides, Inc. (OTCBB: NNVC), said that Anil R. Diwan, PhD, President of the Company, was a participant in a panel on global pharmaceutical strategies at the Fourth Annual Swedish-American Life Sciences Summit held August 20-22, 2008 in Stockholm, Sweden. Speaking in front of a large pharmaceutical and life sciences finance industry group, he enumerated the accomplishments of the Company. He also presented his thoughts on the Company's global strategy for supplying nanoviricides treatments for serious viral diseases to both developed and developing countries.

Dr. Diwan was invited as a panel member on the panel discussion "Emerging Life Sciences in a Global Context- A New Necessity" held last Friday. After discussing the Company's accomplishments, he spoke about the successes of the nanoviricides technology. In response to a question, he said that the Company has a strong focus on commercially important disease targets such as Influenza, Bird Flu, viral diseases of the eye, HIV, and Hepatitis C. He added that the Company has developed a unique broad-spectrum antiviral technology that can work well against a large number of different viruses. Using such agents, it will be possible to develop cost-effective treatment strategies against lethal diseases of the developing world such as Rabies, Dengue virus, and many others. Many of these diseases are now being seen more frequently in developed countries also.

The Fourth SALSS featured leaders of Life Sciences industry in both Sweden and the United States. This forum brought together key pharmaceutical executives, entrepreneurs, venture capitalists and financiers, and key scientists from both countries in an invitation-only open-discussion format.

(http://www.marketwatch.com/news/story/swedish-american-life -science-summit-stockholm/story.aspx?guid=%7B0D2BC44F-BFBF-4F8A-ACA8 -55E5DCEAFC45%7D&dist=hppr).

About NanoViricides:

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(TM) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC, hepatitis C, rabies, dengue fever, and Ebola virus, among others.

Aug 25, 2008 -- Two leaders in cosmetic dentistry, Remedent, Inc. (OTCBB: REMI | Quote | Chart | News | PowerRating) and Den-Mat Holdings, LLC, announced today that Den-Mat has obtained the exclusive rights to manufacture, market and distribute Remedent's innovative GlamSmile(TM) products and technologies in North America and numerous international markets.

Terms of the agreement were not disclosed.

Den-Mat, the maker of the revolutionary LUMINEERS(R) BY CERINATE(R) porcelain veneer laminates, will acquire the rights to Remedent's single-motion veneer placement tray technology, proprietary veneer fabrication technique, and computer imaging design and digital preview technology. Integrating this technology will enable Den-Mat to launch LumiTray(TM), a novel, one tray process for easy and efficient placement of Lumineers.

"This important agreement offers Den-Mat access to Remedent's next generation technology that will further enhance the creation, precision and placement of our high quality Lumineers and new cutting edge products for an improved cosmetic dentistry experience for both professionals and consumers," said Nicholas L. Teti, Jr., Chief Executive Officer of Den-Mat Holdings LLC. "This strategic partnership strengthens Den-Mat as a leader in aesthetic dentistry now and accelerates the Company into the future. We will integrate this new digital process technology into our systems."

Den-Mat will unveil the innovative LumiTray(TM) technology to dental professionals at Destination Education November 7 -- 9, 2008 in Las Vegas, Nevada.

Guy De Vreese, Chairman of Remedent, noted, "By combining GlamSmile(TM) and Lumineers with Den-Mat's substantial customer base and marketing reach, our companies now have a unique opportunity to significantly expand acceptance of our joint veneer technologies in the global dental market. Lumineers is the recognized leader in dental veneers and this strategic alliance with Den-Mat greatly magnifies our ability to penetrate the US dental market, the world's number one dental environment, with our tray delivery system and 3D modeling software for designing and manufacturing veneers."

DLJ Merchant Banking Partners, a private equity investment affiliate of Credit Suisse and owner of Den-Mat Holdings, LLC was instrumental in bringing this agreement to a successful conclusion.

"Den-Mat's integration of this proprietary technology will further enhance its aesthetic offerings and improve customer ease of use and satisfaction," said Ed Johnson, Managing Director and Partner, DLJ Merchant Banking Partners. "We are very excited about the great potential from this transaction for both Den-Mat and Remedent."

About Remedent

Remedent, Inc. develops, manufactures and markets oral care and cosmetic dentistry products with distribution in more than 35 countries. Based in Deurle, Belgium and El Segundo, CA, Remedent serves both the professional dental community and the consumer over-the-counter market.

GlamSmile is a revolutionary cosmetic dental system that substantially expands the consumer and professional dental market for veneers. To produce the veneers, Remedent utilizes high-tech scanning, CAD/CAM design technology, and a proprietary fabrication technique. The veneers are delivered to a dentist already prepared for a simple, single-motion veneer placement. This patent-pending painless delivery system not only dramatically lowers the dentist's cost of installation, but also significantly reduces the amount of time patients spend in the dental chair. The result is unprecedented pricing for veneers which previously were only within the reach of affluent patients.

About Den-Mat Holdings, LLC

California-based Den-Mat Holdings, LLC is a leading manufacturer and marketer of advanced cosmetic and restorative dental products and laboratory services that allow a dentist to preserve, restore and enhance their patient's teeth typically without the requirement for anesthesia, extensive cutting, drilling and tooth removal. This revolutionary type of dentistry not only focuses on superior esthetic results, but on patient comfort and convenience as well.

Den-Mat's revolutionary LUMINEERS(R) BY CERINATE(R) are porcelain veneers that offer a painless way to a permanently whiter and perfectly aligned smile. LUMINEERS are the only porcelain laminates that are strong, reversible, and have a proven record of over 20 years of clinical success. The dentist applies these contact lens-thin veneers to teeth without the need for the shaving and grinding down of sensitive tooth structure that is common with traditional veneers.

Den-Mat currently has approximately 700 employees and manufactures a complete line of more than 200 cosmetic and restorative formulations. The company services approximately 40,000 dentists worldwide, and offers variety of educational seminars and marketing support services for dentists. F

About Credit Suisse

As one of the world's leading banks, Credit Suisse provides its clients with investment banking, private banking and asset management services worldwide. Credit Suisse offers advisory services, comprehensive solutions and innovative products to companies, institutional clients and high-net worth private clients globally, as well as retail clients in Switzerland. Credit Suisse is active in over 50 countries and employs approximately 40,000 people. Credit Suisse's parent company, Credit Suisse Group, is a leading global financial services company headquartered in Zurich. Credit Suisse Group's registered shares (CSGN) are listed in Switzerland and, in the form of American Depositary Shares (CS), in New York.

Aug 25, 2008 -- Somatic Systems, Inc. (PINKSHEETS: SMAS | Quote | Chart | News | PowerRating) announced today that it has completed its first round of share buybacks and retired one billion shares of its common stock. The cancellation of these shares will become effective by the end of the day, and is expected to increase shareholder value considerably.

Prior to retiring these shares, Somatic Systems had approximately 8 billion shares of common stock issued and outstanding. Cancellation of these shares brings the structure down to approximately 7 billion shares, reducing the company's common stock by over 12%.

The sizable elimination of shares comes less than 3 business days after Somatic Systems announced it would begin a massive share acquisition and cancellation program, to restructure the company's capital and grow share price without conducting a reverse split of the stock.

The company stated its intention to continue to acquire and retire additional shares. "This significant cancellation of shares is just the beginning," stated Somatic Systems CEO Steven Aronstein. "In addition to the strong efforts we are making to grow our market value by building our business through expansion and aggressive promotion and strategic contracts, we believe that removing as much as half our shares can help grow our value exponentially. We are just getting started."

Somatic Systems stated it will continue to announce the acquisition and retirement of shares as they are pending or have been completed in the coming weeks.

About Somatic Systems, Inc.

Somatic Systems is the worldwide center for Clinical Somatics(TM), the groundbreaking drug-free, non-surgical approach to pain relief. This proprietary system uses natural, non-invasive movement techniques -- conducted through one-hour hands-on sessions, therapeutic exercises classes, and home exercises lasting as little as 5 minutes a day -- to relieve pain and limitation resulting from accident, trauma and repetitive stress, including back pain, knee pain, joint problems, carpal tunnel syndrome, TMJ, scoliosis, bursitis, sciatica, headaches, tendonitis and more. Clinical Somatics(TM) also provides performance gains and injury prevention for casual and professional athletes.

Somatic Systems is pursuing a 3-part growth strategy, consisting of a nationwide rollout of pain management Somatics Clinics; increased production and distribution of therapeutic videos, books, and other retail self-help Somatics Products; and expanded Somatics Training Programs to supply Clinic practitioners serving medical and orthopedic professionals and institutional and corporate programs.

Aug 25, 2008 -- VIASPACE Inc. (OTCBB: VSPC), a company that transforms proven space and defense technologies from NASA and the Department of Defense into hardware and software solutions, announced today that it has entered into an agreement with WonATech of Korea for VIASPACE to sell and distribute WonATech's fuel cell test stations outside Korea.

Fuel Cell test stations that can test hydrogen, liquid and solid based fuel cells are an expanding portion of the $54 Billion clean energy market. WonATech offers sophisticated single and multi-channel fuel cell test stations that represent high end products at attractive prices for fuel cell and automotive manufacturers in Japan, Europe and the United States. Hundreds of universities throughout the world are also engaged in fuel cell research, but must deal with the reality of limited budgets when it comes to equipment purchases.

Since its establishment in 1991, WonATech has concentrated its efforts in the development of products related to electrochemical application. Steadily supplying products in experimental research fields and industrial sites, WonATech has played a leading role in this field of business. Their product line includes potentiostats, battery cyclers, fuel cell test stations, heating chambers, temperature monitors, voltage monitors and associated software.

VIASPACE CEO Carl Kukkonen stated, "We are very pleased with this new agreement, granting VIASPACE rights to distribute WonATech's fuel cell test station product line. This line of fuel cell test stations will be attractive to many of the customers who have or will purchase the HS-1000 VIASENSOR, our real time laser based humidity sensor, such as Ballard or 3M Corporation, along with the major automobile manufacturers who are currently designing fuel cell powered vehicles."

About VIASPACE: Founded in 1998 with the objective of transforming proven space and defense technologies from NASA and the Department of Defense into hardware and software solutions that solve today's complex problems, VIASPACE benefits from important patent and software licenses from Caltech, which manages NASA's Jet Propulsion Laboratory.

About Standoutstocks.com Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies. Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at www.Standoutstocks.com and select the "join now" button.

Join us at www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.standoutstocks.com/disclaimer.aspx

CONTACT: Standoutstocks.com e-mail: info@standoutstocks.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index